Chemed (NYSE:CHE) Upgraded at Wall Street Zen

Posted by Stanley Muller on Oct 13th, 2026

Wall Street Zen upgraded shares of Chemed (NYSE:CHE – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Other equities analysts also recently issued reports about the stock. Bank of America reaffirmed a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Oppenheimer increased their target price on shares of Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Weiss Ratings raised Chemed from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday. Royal Bank Of Canada raised their target price on Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a research note on Thursday, July 30th. Finally, UBS Group began coverage on Chemed in a report on Friday, September 25th. They set a “buy” rating and a $650.00 price target on the stock. Two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $554.60.

Check Out Our Latest Research Report on CHE

Chemed Trading Up 0.1%

NYSE:CHE opened at $500.46 on Friday. The company has a fifty day moving average of $520.47 and a 200 day moving average of $467.89. Chemed has a 52 week low of $365.20 and a 52 week high of $557.00. The company has a quick ratio of 0.89, a current ratio of 0.91 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $6.54 billion, a P/E ratio of 25.14, a P/E/G ratio of 2.01 and a beta of 0.51.

Chemed (NYSE:CHE – Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, beating the consensus estimate of $5.60 by $0.46. The business had revenue of $673.25 million during the quarter, compared to analysts’ expectations of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.27 EPS. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, research analysts predict that Chemed will post 23.55 earnings per share for the current year.

Chemed Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Monday, August 17th were paid a $0.70 dividend. The ex-dividend date of this dividend was Monday, August 17th. This is a positive change from Chemed’s previous quarterly dividend of $0.60. This represents a $2.80 dividend on an annualized basis and a yield of 0.6%. Chemed’s payout ratio is 14.06%.

Insider Activity at Chemed

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction on Monday, September 28th. The shares were sold at an average price of $513.45, for a total value of $1,026,900.00. Following the completion of the transaction, the chief executive officer directly owned 66,418 shares in the company, valued at approximately $34,102,322.10. This represents a 2.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Patrick P. Grace sold 190 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $532.00, for a total transaction of $101,080.00. Following the completion of the transaction, the director owned 3,533 shares of the company’s stock, valued at $1,879,556. This trade represents a 5.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 9,190 shares of company stock worth $4,833,160 over the last quarter. Corporate insiders own 3.33% of the company’s stock.

Institutional Investors Weigh In On Chemed

A number of large investors have recently modified their holdings of CHE. BlackRock Inc. bought a new stake in shares of Chemed during the second quarter valued at approximately $691,290,000. Bank of America Corp DE purchased a new position in Chemed in the 2nd quarter worth approximately $48,255,000. Caisse de depot et placement du Quebec bought a new position in Chemed in the 2nd quarter valued at approximately $44,309,000. Bank of New York Mellon Corp bought a new position in Chemed in the 2nd quarter valued at approximately $43,800,000. Finally, First Trust Advisors LP lifted its position in Chemed by 24.7% in the 1st quarter. First Trust Advisors LP now owns 236,392 shares of the company’s stock valued at $89,295,000 after acquiring an additional 46,791 shares in the last quarter. Institutional investors own 95.85% of the company’s stock.

Chemed Company Profile

(Get Free Report)

Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.